Volume Alert - CLDX 18.49 Celldex Therapeutics Inc $CLDX

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - CLDX 18.49 Celldex Therapeutics Inc $CLDX Hit a high today of 18.71 Closing the day 10:30 at 18.49 +0.77 +4.35% With a day low of 17.47 and a total volume of 1,610,876.

CLDX Recent Posts: http://investorshangout.com/Celldex-Therapeut...LDX-53702/

CLDX Celldex Therapeutics Inc Recent Headline News

Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst Blog
Arpita Dutt - Zacks Investment Research - 1 hr 57 mins ago
Regulatory updates from Gilead (GILD) and Regeneron (REGN) and Geron's (GERN) deal with J&J were the highlights last week in the biotech sector.
GILD: 102.10 (-1.61), GERN: 3.20 (+0.03), CLDX: 19.06 (+1.34), CYTR: 2.69 (+0.17), AMGN: 162.63 (+0.39), ABBV: 65.67 (-0.38), REGN: 417.20 (+3.98)

Celldex Therapeutics Surges on Positive Rindopepimut Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:05PM CST
Celldex Therapeutics announced encouraging interim update from the phase II ReACT study evaluating the use of rindopepimut.
ACT: 268.40 (-1.20), CLDX: 19.06 (+1.34), ABBV: 65.67 (-0.38)

Why Celldex Therapeutics' Stock Is Now Ready For Takeoff
Brian Nichols - at Seeking Alpha - Tue Nov 18, 1:44PM CST

CLDX: 19.06 (+1.34), ALXN: 193.71 (+1.34)

Celldex Therapeutics (CLDX) Stock Sells Off Today Following Monday's Gains
at The Street - Tue Nov 18, 10:47AM CST
Shares of Celldex Therapeutics (CLDX) dipped Tuesday after the stock surged Monday following the company's announcement of positive results of its immunotherapy in treating a certain type of brain tumor.
CLDX: 19.06 (+1.34)

Celldex Therapeutics To Enter Talks With FDA
Steven Giardino - Seeking Alpha - Tue Nov 18, 9:26AM CST
On Friday, Celldex Therapeutics (NASDAQ: CLDX ) announced results from a recently near completed Ph II trial testing Rindopepimut in recurrent glioblastoma ((rGBM)). The 72 patient, randomized, placebo controlled study (gold standard of trial design)...
NWBO: 5.26 (-0.13), CLDX: 19.06 (+1.34), SRPT: 15.97 (+0.40)

Critical Alerts For Kinder Morgan, Celldex Therapeutics, Baker Hughes Inc., RF Micro Devices and SolarCity Released By InvestorsObserver
PR Newswire - Tue Nov 18, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for KMI, CLDX, BHI, RFMD and SCTY.
KMI: 40.68 (+0.27), SCTY: 54.93 (-0.71), CLDX: 19.06 (+1.34), RFMD: 13.73 (-0.02), BHI: 63.25 (-0.30)

Celldex Therapeutics, Inc. (CLDX) in Focus: Stock Soars 28.9% - Tale of the Tape
Vaishali Doshi Shah - Zacks Investment Research - Tue Nov 18, 8:18AM CST
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as the company saw its shares rise by almost 29% on the day.
ANIP: 56.54 (+0.88), CLDX: 19.06 (+1.34), AMAG: 35.50 (+0.16), AFFX: 8.75 (-0.83)

Look for Shares of Celldex Therapeutics to Potentially Pullback after Yesterday's 28.88% Rise
Comtex SmarTrend(R) - Mon Nov 17, 4:40PM CST
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $16.30 to a high of $19.48. Yesterday, the shares gained 28.9%, which took the trading range above the 3-day high of $15.27 on volume of 22.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CLDX: 19.06 (+1.34)

Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago Celldex Therapeutics Is Down 14.6% (CLDX)
Comtex SmarTrend(R) - Mon Nov 17, 3:58PM CST
When Celldex Therapeutics (NASDAQ:CLDX) reported earnings a week ago on November 4th, 2014, analysts, on average, expected the company to report a loss of $0.33 on sales of $324.0 thousand. Celldex Therapeutics actually reported a loss of $0.31 per share on sales of $1.1 million, beating EPS estimates by $0.02 and beating revenue estimates by $0.8 million. Shares of Celldex Therapeutics have slipped from $16.58 to $14.16, representing a loss of 14.6%, since the company reported earnings 13 days ago.
CLDX: 19.06 (+1.34)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:47AM CST

CADC: 5.11 (-0.32), ANV: 1.76 (-0.28), BONE: 3.14 (-0.02), WLH: 19.17 (+0.01), CLDX: 19.06 (+1.34), ENZY: 8.20 (-0.05), TGEN: 5.54 (-0.68), CHOP: 2.10 (-0.03), MSBF: 9.90 (-0.01), NVGN: 1.75 (-0.05), DWA: 22.54 (+0.06), WHX: 2.26 (-0.08), VYFC: 19.69 (-0.06), VGGL: 3.18 (-0.23), SNSS: 2.18 (+0.11), DNR: 9.85 (-0.16), MOBI: 5.58 (-0.31), VPCO: 1.58 (-0.01), FOLD: 6.68 (-0.07), ATEA: 1.35 (-0.11)

Celldex Therapeutics (CLDX) Stock Surges Following Brain Tumor Immunotherapy Results
at The Street - Mon Nov 17, 10:02AM CST
Shares of Celldex Therapeutics (CLDX) were up in morning trading Monday after the company announced positive results of its immunotherapy in treating a certain type of brain tumor.
CLDX: 19.06 (+1.34)

Celldex Therapeutics: Interim Results For Phase 2 ReACT Trial Are Very Encouraging
Smith On Stocks - at Seeking Alpha - Mon Nov 17, 9:28AM CST

CLDX: 19.06 (+1.34)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:15AM CST

CADC: 5.11 (-0.32), INO: 9.55 (-0.31), CLDX: 19.06 (+1.34), HAL: 48.45 (-0.09), ROX: 1.57 (-0.21), SNSS: 2.18 (+0.11), DNR: 9.85 (-0.16), DWA: 22.54 (+0.06), GSAT: 2.66 (+0.11), CMGE: 25.46 (-0.70), FOLD: 6.68 (-0.07), BHI: 63.27 (-0.28)

Celldex up premarket on positive rindopepimut data
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 7:57AM CST

CLDX: 19.06 (+1.34)

Biotech Equities Technical Coverage - Orexigen Therapeutics, Novavax, Sunesis Pharma, Celldex Therapeutics, and Navidea Biopharma
PR Newswire - Mon Nov 17, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Orexigen Therapeutics Inc. (NASDAQ: OREX), Novavax Inc. (NASDAQ: NVAX), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, November 14, 2014, the NASDAQ Composite ended at 4,688.54, up 0.18%, the Dow Jones Industrial Average edged 0.10% lower, to finish the day at 17,634.74, and the S&P 500 closed at 2,039.82, up 0.02%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 777.26, down 0.83%, while the index has advanced 9.80% in the last one month. Register for your complimentary reports on these five stocks at:
OREX: 5.72 (+0.10), NAVB: 1.20 (unch), NVAX: 4.96 (-0.05), CLDX: 19.06 (+1.34), SNSS: 2.18 (+0.11)

Celldex Therapeutics' (CLDX) CEO Presents Phase 2 ReACT Interim Data at the Society for Neuro-Oncology Annual Meeting (Transcript)
SA Transcripts - at Seeking Alpha - Fri Nov 14, 10:53PM CST

CLDX: 19.06 (+1.34)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 4:38PM CST

HK: 2.90 (+0.02), NTES: 100.11 (-1.79), CIG: 4.88 (-0.01), TSRO: 30.75 (-0.70), DDD: 36.01 (+0.64), CLDX: 19.06 (+1.34), SCMP: 11.95 (-0.10), BVN: 9.76 (-0.01), ABGB: 15.23 (+0.83), SSE: 10.33 (-0.07)

Interim Update from Randomized Phase 2 ReACT Study of Rindopepimut in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Survival Benefit
GlobeNewswire - Fri Nov 14, 2:35PM CST
-Benefit observed across multiple endpoints in bevacizumab-naïve patients-
CLDX: 19.06 (+1.34)

Celldex Immunotherapy Prolongs Survival for Recurrent Brain Tumor Patients
at The Street - Fri Nov 14, 2:35PM CST
Positive data presented Friday, particularly the statistically significant survival benefit favoring patients treated with rindopepimut, has Celldex planning -- cautiously -- for a conversation with the FDA about accelerated approval.
CLDX: 19.06 (+1.34)

Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 59.55 (-0.34), INCY: 71.57 (+1.93), CLDX: 19.06 (+1.34), NLNK: 33.18 (+0.52), GSK: 46.32 (+0.04), BMY: 58.55 (-0.15), SRNE: 4.00 (unch)

Celldex Therapeutics Inc (CLDX) Stock Research Links

CLDX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 36

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Childhood Nutrition Advice That Lowers Mealtime Stress

Updated Category News Views 47

A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...

Continue Reading
Prospera’s DFW Culture Win Matters Beyond the Plaque

Updated Category News Views 46

Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...

Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap

Updated Category News Views 86

Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...

Continue Reading
VIGGO’s Mix1Pro Tests Practical Commercial Cleaning

Updated Category News Views 61

A cleaning robot earns its keep in the ugly corners, not under convention-center lights. VIGGO used the ISSA Show North America gathering in Las Vegas, held November 17–19, 2026, to introduce the Mix1Pro, a compact commercial machine aimed at indoor facilities below 53,800 square feet. That target matters. Smaller, messier sites are where autonomy can look terrific on a...

Continue Reading
Shenzhen’s 50-Year Message Carries Real Trade Weight

Updated Category News Views 68

A city once framed as a frontier fishing village is being presented as China’s sharpest recent economic before-and-after picture. At the welcome dinner for the 33rd APEC Economic Leaders’ Meeting in Shenzhen, President Xi Jinping gave guests a compact geographic guide to China’s past: Xi’an for thousands of years, Beijing for 500 years, Shanghai for 100 years, and...

Continue Reading
Swim Readiness Depends on Skills, Not Birthdays Alone

Updated Category News Views 55

A child popping up calmly after a brief dunk tells you more than a birthday ever will. That is the sensible center of Woody Alpern's guidance for families weighing whether a child belongs in the next swim level. The Atlanta swim school expert's point is refreshingly free of the usual parental race: advancement is earned through repeatable skills, comfort, and judgment in...

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 70

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
Franklin County Trees Raise Funds and Honor Veterans

Updated Category News Views 46

Holiday charity works best when it gives people something tangible to gather around, and Franklin County has found a pretty sturdy version of that formula. Its eighth annual Festival of Trees opens at 4 p.m. Saturday, November 21, at the Franklin County 11/30 Visitors Center in downtown Chambersburg, carrying the theme A Salute To Veterans. More than 80 decorated trees...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Recent Class Action Against Fluor Corporation Investors

Updated Category News Views 230

Class Action Lawsuit Against Fluor Corporation Recently, a prominent plaintiffs' law firm has taken action against Fluor Corporation (NYSE: FLR) in order to advocate for investors who acquired shares within a specific period. Key Information for Investors Investors who purchased FLR securities during the designated time frame could become lead plaintiff representatives,...

Continue Reading
Harnessing Apple Stock Dividends for a Steady Income Stream

Updated Category News Views 313

Understanding Apple Stock's Dividend Potential Apple Inc. (NASDAQ: AAPL) has made significant strides in the tech industry, and with a strong performance in the stock market, many investors are looking at ways to monetize their investments through dividends. As shares of Apple continue to perform impressively, the company is on track to reach a staggering $4 trillion...

Continue Reading
Transforming Finance: Infosys BPM Introduces AI Automation

Updated Category News Views 244

Revolutionizing Finance with AI-Powered Solutions Infosys BPM is making waves in the finance and accounting services sector with its innovative AI agents designed to enhance operational efficiency. This new solution addresses the pivotal component of accounts payable, where businesses can now witness significant efficiency gains, improved accuracy, and a superior user...

Continue Reading
Bitmine Immersion Technologies Boosts Crypto Holdings to $10.7B

Updated Category News Views 288

Bitmine Immersion Technologies Expands Crypto Holdings Significantly Bitmine Immersion Technologies, Inc. has made headlines by announcing its impressive digital asset portfolio, which now includes 4.285 million Ethereum (ETH) tokens, totaling a staggering $10.7 billion in crypto and total cash holdings. This remarkable achievement illustrates the company's steadfast...

Continue Reading
CIB Marine Bancshares Shares Positive Earnings Growth Insights

Updated Category News Views 190

CIB Marine Bancshares, Inc. Delivers Strong Third Quarter Results BROOKFIELD, Wis. — CIB Marine Bancshares, Inc. (the Company or CIB Marine) (OTCQX: CIBH), the holding entity for CIBM Bank, reported an impressive performance for the third quarter of 2025, revealing an uptick in both net interest income and operational improvements in the banking and mortgage divisions....

Continue Reading